CD19 and lymphoma: In 2017, two studies, the phase II ZUMA-1 [35] trial led by Sattva Neelapu and a case-series study led by Carl June, validated the efficacy of CD19 CAR-T cells in patients with refractory B-cell leukemia and lymphoma.